002581.SHE Shandong Sinobioway Biomedicine Co Ltd
- Market cap
- CNY 2.76B
- P/E
- -
- P/B
- 1.56x
- ROE
- -10.4%
- Dividend yield
- 0.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002581.SHE undervalued?
Graham numberThe Graham number of Shandong Sinobioway Biomedicine Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Sinobioway Biomedicine Co Ltd fundamental analysis
No fundamental analysis for Shandong Sinobioway Biomedicine Co Ltd yet.
Shandong Sinobioway Biomedicine Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Sinobioway Biomedicine Co Ltd
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. It offers injectable mouse nerve growth factor, human interferon, vaccines, traditional Chinese medicine decoction pieces, and pharmaceutical distribution. The company was founded in 1998 and is based in Shenzhen, China. Shandong Sinobioway Biomedicine Co., Ltd. is the subsidiary of Shenzhen Yilian Technology Co., Ltd.
Full company profileShandong Sinobioway Biomedicine Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Sinobioway Biomedicine Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.26B | 1.16B | 665M | 568M | 277M | 403M | 357M | 430M | 360M | 275M | 259M |
| Gross Profit | 966M | 907M | 566M | 493M | 222M | 317M | 280M | 337M | 273M | 145M | 31.7M |
| Operating Income | 447M | 467M | -87.6M | 79.0M | -196M | 273M | 33.7M | -293M | -111M | -142M | -180M |
| EBITDA | 517M | 532M | 48.0M | 176M | -117M | 347M | 88.0M | -236M | -105M | -136M | -180M |
| Net Income | 418M | 388M | -104M | 63.4M | -196M | 271M | -14.7M | -332M | -137M | -116M | -182M |
| EPS | 0.63 | 0.59 | -0.16 | 0.10 | -0.30 | 0.41 | -0.02 | -0.50 | -0.21 | -0.18 | -0.28 |
| Balance Sheet | |||||||||||
| Total Assets | 2.69B | 4.00B | 4.29B | 3.41B | 2.44B | 2.76B | 2.86B | 2.34B | 2.20B | 2.17B | 2.04B |
| Total Liabilities | 160M | 1.08B | 1.47B | 1.03B | 254M | 287M | 389M | 163M | 174M | 222M | 205M |
| Shareholders' Equity | 2.47B | 2.86B | 2.75B | 2.31B | 2.12B | 2.39B | 2.39B | 2.07B | 1.92B | 1.84B | 1.75B |
| Cash & Short-term Investments | 769M | 1.82B | 1.55B | 1.12B | 284M | 188M | 184M | 152M | 506M | 220M | 209M |
| Total Debt | 950K | 892M | 1.24B | 845M | 167M | 177M | 165M | 14.5M | 2.77M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 169M | 271M | 74.5M | 48.4M | 18.5M | -46.0M | -54.5M | -36.5M | -6.55M | -254M | - |
| Capital Expenditure | 44.7M | 88.1M | 608M | 36.3M | 67.7M | 60.8M | 31.5M | 4.32M | 9.01M | 180M | 61.9M |
| Free Cash Flow | 125M | 183M | -534M | 12.1M | -49.2M | -107M | -85.9M | -40.8M | -15.6M | -433M | -186M |
| Ratios | |||||||||||
| ROE | 16.9% | 13.6% | -3.8% | 2.7% | -9.3% | 11.3% | -0.6% | -16.1% | -7.1% | -6.3% | -10.4% |
| ROA | 15.5% | 9.7% | -2.4% | 1.9% | -8.0% | 9.8% | -0.5% | -14.2% | -6.3% | -5.4% | -8.9% |
| Net Profit Margin | 33.0% | 33.4% | -15.6% | 11.2% | -70.8% | 67.3% | -4.1% | -77.4% | -38.1% | -42.3% | -70.4% |
| Debt to Equity | 0.00x | 0.31x | 0.45x | 0.37x | 0.08x | 0.07x | 0.07x | 0.01x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shandong Sinobioway Biomedicine Co Ltd dividends
- Dividend yield
- 0.04%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 21, 2016
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.14M | 0.00 | - |
| 2024 | CNY 177K | 0.00 | - |
| 2023 | CNY 10.3M | 0.02 | - |
| 2022 | CNY 8.04M | 0.01 | - |
| 2021 | CNY 6.71M | 0.01 | 2.5% |
| 2020 | CNY 55.3M | 0.08 | - |
| 2019 | CNY 60.4M | 0.09 | 95.3% |
| 2018 | CNY 75.5M | 0.11 | - |
| 2017 | CNY 50.9K | 0.00 | 0.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jul 10, 2015.
Who owns Shandong Sinobioway Biomedicine Co Ltd
- Insiders 38.25%
- Institutions 5.37%
- Public & others 56.38%
- Shares outstanding 660M
- Free float 512M
Shandong Sinobioway Biomedicine Co Ltd company profile
- Company name
- Shandong Sinobioway Biomedicine Co Ltd
- Ticker
- 002581.SHE
- ISIN
- CNE1000012Y5
- Exchange
- Shenzhen Stock Exchange
- Listed since
- May 5, 2011
- Sector
- Healthcare
- Industry
- Chemicals
- Employees
- 492
- Fiscal year end
- December
- Address
- Qimei Building, Shenzhen, China, 255000
- Phone
- 86 75 5869 50185
- Website
- wmm.bio
About Shandong Sinobioway Biomedicine Co Ltd
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. It offers injectable mouse nerve growth factor, human interferon, vaccines, traditional Chinese medicine decoction pieces, and pharmaceutical distribution. The company was founded in 1998 and is based in Shenzhen, China. Shandong Sinobioway Biomedicine Co., Ltd. is the subsidiary of Shenzhen Yilian Technology Co., Ltd.
Shandong Sinobioway Biomedicine Co Ltd management
6- Mr. Jialin YueChairman & GM · born 1968
- Mr. Juan Xiong XuDeputy GM & Vice Chairman · born 1986
- Ms. Ting ZhouFinancial Director, Head of Accounting & Employee Director · born 1988
- Ms. Xiaoru ShiSecretary to the Board & Non-Independent Director · born 1996
- Mr. Ren YanshenCo-Founder
- Mr. Chen ZhangliangCo-Founder